drugset / Trial / NCT05421416

Loratadine for the Prevention of G-CSF-related Bone Pain

NCT05421416

Phase 2 Recruiting 78 enrolled AHS Cancer Control Alberta
RandomizedParallel-groupTriple-blindPrevention

Summary

The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.

Timeline

Start
2024-11-28
Primary completion
2026-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg